WO2021230340A1 - 新規吸入剤 - Google Patents
新規吸入剤 Download PDFInfo
- Publication number
- WO2021230340A1 WO2021230340A1 PCT/JP2021/018328 JP2021018328W WO2021230340A1 WO 2021230340 A1 WO2021230340 A1 WO 2021230340A1 JP 2021018328 W JP2021018328 W JP 2021018328W WO 2021230340 A1 WO2021230340 A1 WO 2021230340A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cepharanthin
- inhalation
- inhalant
- powder
- present
- Prior art date
Links
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 claims abstract description 56
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 claims abstract description 56
- 239000000843 powder Substances 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 16
- 229940041682 inhalant solution Drugs 0.000 claims description 6
- 208000025721 COVID-19 Diseases 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- 229940124597 therapeutic agent Drugs 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 210000002345 respiratory system Anatomy 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000006199 nebulizer Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 241001678559 COVID-19 virus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000004631 alopecia areata Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 239000003595 mist Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 244000184734 Pyrus japonica Species 0.000 description 2
- 240000007267 Stephania hernandifolia Species 0.000 description 2
- 241000271897 Viperidae Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007561 laser diffraction method Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 201000004480 serous glue ear Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- WTXHFWYAETTXNF-XZWHSSHBSA-N (+)-Isotetrandrine Natural products O(C)c1c(OC)cc2c3[C@H](N(C)CC2)Cc2cc(c(OC)cc2)Oc2cc(ccc2)C[C@@H]2N(C)CCc4c2cc(c(OC)c4)Oc13 WTXHFWYAETTXNF-XZWHSSHBSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ANOXEUSGZWSCQL-LOYHVIPDSA-N Cycleanine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3N(C)CCC=4C=C(OC)C(OC)=C(C3=4)O3)C=21)OC)OC)C1=CC=C3C=C1 ANOXEUSGZWSCQL-LOYHVIPDSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- ANOXEUSGZWSCQL-UHFFFAOYSA-N O-Methyl-isochondodendrin Natural products O1C(C2=3)=C(OC)C(OC)=CC=3CCN(C)C2CC(C=C2)=CC=C2OC(C=23)=C(OC)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 ANOXEUSGZWSCQL-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000950638 Symphysodon discus Species 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- HOQADATXFBOEGG-UHFFFAOYSA-N isofenphos Chemical compound CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C HOQADATXFBOEGG-UHFFFAOYSA-N 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- WVTKBKWTSCPRNU-XZWHSSHBSA-N isotetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-XZWHSSHBSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the present invention relates to an inhalant containing cepharanthin.
- COVID-19 Japanese name: new coronavirus infection
- SARS-CoV-2 2019 new coronavirus
- COVID-19 is an infectious disease that was confirmed to occur in Wuhan, People's Republic of China in November 2019 and was reported to WHO in December of the same year, and the infection has spread worldwide since then.
- the symptoms begin with fever, dry cough, fatigue, sputum, shortness of breath, sore throat, headache, myalgia, arthralgia, olfactory dysfunction, taste dysfunction, etc.
- pneumonia becomes severe and causes respiratory failure, resulting in death. Is to take.
- Non-Patent Document 1 a large number of existing drugs have been screened, and recently, cepharanthin is expected as a therapeutic agent for COVID-19.
- An object of the present invention is to provide a new drug for the prevention and / or treatment of a disease based on SARS-CoV-2 infection, COVID-19.
- cepharanthin powders and tablets for oral administration, and injections are used.
- the present inventors have conceived to apply cepharanthin, which is considered to be an effective drug for suppressing SARS-CoV-2 infection, to the site most infected with SARS-CoV-2.
- cepharanthin as an inhaler that can be directly applied to the lower respiratory tract, and further, by setting the particle size of cepharanthin to 0.5 to 10 ⁇ m, the efficiency of cepharanthin directly to the lower respiratory tract is achieved.
- the present invention has been completed by finding that a well-supplyable inhaler can be obtained.
- the present invention provides an inhalant containing cepharanthin. Further, when the particle diameter of cepharanthin is 0.5 to 10 ⁇ m as the aerodynamic particle diameter and the median diameter of the aerodynamic mass of cepharanthin is 0.5 to 10 ⁇ m, cepharanthin efficiently reaches the lower respiratory tract.
- cepharanthin which is considered to be an effective drug for suppressing infection of SARS-CoV-2, can be directly supplied to the lower respiratory tract.
- the inhalant of the present invention is a preparation that inhales cepharanthin as an aerosol and applies it to the lower respiratory tract.
- Cepharanthine used in the present invention is a chemical substance having a chemical name of 6', 12'-Dimethoxy-2, 2'-dimethyl-6,7- [methylenebis (oxy)] oxyacanthan, and is a chemical substance having a chemical name of 6', 12'-Dimethoxy-2, 2'-Dimethyl-6,7- , A type of alkaloid that can be extracted from Stephania japonica, etc.
- Cepharanthine is used to treat leukopenia caused by radiation, alopecia areata / alopecia areata, serous glue ear, and pit viper bite.
- cepharanthin is used as an inhaler as in the present invention, in addition to these indications, it is particularly useful as an infection suppressant for SARS-CoV-2 and a prophylactic and / or therapeutic agent for COVID-19.
- cepharanthin either chemically synthesized cepharanthin or extracted from Tuzla japonica, Menispermaceae japonica, Stephania japonica, etc. can be used.
- Tamasaki Tsuzurafuji it is also possible to use Tamasaki Tsuzurafuji extract containing other alkaloids other than cepharanthin such as isotetrandrine, cycleanin, and velbamine in addition to cepharanthin.
- Cepharanthine and Tamasaki Tsuzurafuji extract are commercially available and can be purchased and used, and Tamasaki Tsuzurafuji extract can be produced from Tamasaki Tsuzurafuji by using a known method.
- the particle size of cepharanthin is 0.5 to 10 ⁇ m from the viewpoint of reachability to the lower respiratory tract. It is more preferably 8 ⁇ m, and even more preferably 2 to 8 ⁇ m.
- the aerodynamic mass median diameter of cepharanthin is preferably 0.5 to 10 ⁇ m, more preferably 1 to 8 ⁇ m, and even more preferably 2 to 8 ⁇ m.
- the particle size of cepharanthin is the particle size of the cepharanthin-containing powder in the case of powder, and the particle size of the spray droplet containing cepharanthin in the case of a liquid agent.
- this particle size can be adjusted by pulverization, sieving, etc. at the time of powder production.
- spray droplets it may be appropriately adjusted according to the form of the nebulizer (jet type, ultrasonic type, mesh type, etc.) used when inhaling the liquid agent.
- the form of the inhalant of the present invention includes, but is not limited to, an inhalation powder agent, an inhalation liquid agent, and an inhalation aerosol agent.
- an appropriate device or device for inhalation administration may be used, or a container including an inhalation device may be filled.
- the inhalation powder is a preparation to be inhaled as an aerosol of a cepharantin-containing powder prepared so that the inhalation amount is constant, and the cepharantin-containing powder is preferably 0.5 to 10 ⁇ m, more preferably 1 to 8 ⁇ m, still more preferably. It may be prepared as a powder having a particle size of 2 to 8 ⁇ m, specifically, an aerosol medium diameter of preferably 0.5 to 10 ⁇ m, more preferably 1 to 8 ⁇ m, still more preferably 2 to 8 ⁇ m. It may be prepared as a powder having. Sugar or sugar alcohol can also be used as an additive in the cepharanthin-containing powder.
- examples of sugar include lactose hydrate, sucrose, glucose and the like
- examples of sugar alcohols include erythritol, isomalt, lactitol, maltitol, mannitol, sorbitol, xylitol and the like.
- Specific examples of the inhalation powder agent include a dry powder inhaler (hereinafter abbreviated as DPI).
- DPI dry powder inhaler
- the device usually used as DPI can be used.
- a device using a capsule includes a monohaler, a handy heller, a breeze heller, a flow cap, and the like.
- Reservoir-type devices filled with powder in a container include a turbuler, a click heller, a swing heller, a twist heller, and the like.
- the inhalation solution is a liquid inhalation preparation that is inhaled by a nebulizer or the like.
- Cepharanthine may be dissolved or suspended in a suitable solvent to prepare a solution or suspension.
- an tonicity agent, a pH adjuster, or the like can be added.
- the droplet of the inhalant liquid is preferably 0.5 to 10 ⁇ m, more preferably 1 to 8 ⁇ m, still more preferably 2 to 8 ⁇ m, depending on the form of the nebulizer (jet type, ultrasonic type, mesh type, etc.).
- the aerodynamic mass median diameter may be adjusted to a droplet of preferably 0.5 to 10 ⁇ m, more preferably 1 to 8 ⁇ m, still more preferably 2 to 8 ⁇ m.
- cepharanthin registered trademark
- cepharanthin (registered trademark) Note manufactured and sold by Medisa Shinyaku Co., Ltd. can be used.
- cepharanthin (registered trademark) injection may be used as it is or diluted with an appropriate solvent and inhaled using a nebulizer.
- a device used for the inhalation solution of the present invention a device usually used as a nebulizer can be used.
- a type that atomizes the chemical solution with compressed air (jet type)
- a type that atomizes the chemical solution using the vibration of an ultrasonic vibrator (jet type)
- a mist that pushes the chemical solution out of a hole in the mesh by vibration
- An example is a type (mesh type) that makes a shape.
- the inhalation aerosol is a fixed-quantity spray inhaler that can spray a certain amount of cepharanthin together with the propellant filled in the container.
- the spray droplet sprayed by the inhalation aerosol agent is preferably 0.5 to 10 ⁇ m, more preferably 0.5 to 10 ⁇ m, depending on the composition of the solution or suspension of cepharanthin, the propellant to be filled, the shape of the nozzle which is a member of the container, and the like.
- the spray droplets may be adjusted to 1 to 8 ⁇ m, more preferably 2 to 8 ⁇ m, and specifically, the aerodynamic mass medium diameter is preferably 0.5 to 10 ⁇ m, more preferably 1 to 8 ⁇ m, still more preferably.
- Inhalation aerosols are made by dissolving or suspending cepharanthin in a suitable solvent, preparing a solution or suspension, filling a pressure resistant container with a liquid propellant, and installing a metering valve. be able to. Dispersants, stabilizers and the like can be added when preparing the solution or suspension. Specific examples of the inhalation aerosol agent include a pressurized dose inhaler.
- the inhalant of the present invention is an alopecia areata / alopecia areata, serous glue ear, and pit viper bite, which are indications for cepharanthin, as well as a SARS-CoV-2 infection inhibitor, COVID-19 prevention and /.
- it can be used as a therapeutic agent.
- the dose varies depending on the weight, age, sex, symptoms, etc. of the patient, but usually, for adults, the range of cepharanthin is in the range of 1 to 20 mg per day.
- the inhalant of the present invention when used as an infection inhibitor of SARS-CoV-2, a prophylactic and / or therapeutic agent of COVID-19, it can be used in combination with an anti-HIV agent such as nelfinavir.
- Example 1 98.5 g of lactose hydrate was added to 1.5 g of cepharanthin crushed by a jet mill (particle size: 1.2 ⁇ m: measured by laser diffraction method), and Hiflex Gural (manufactured by Fukae Pautech Co., Ltd., HF-GS-). 2J) was mixed. 0.1 g of the obtained powder was filled in a capsule to produce an inhalation powder.
- Comparative Example 1 Add 98.5 g of lactose hydrate to 1.5 g of unground cepharanthin (particle size: 50 ⁇ m: measured by laser diffraction method) and mix with Hiflex Gural (manufactured by Fukae Pautech Co., Ltd., HF-GS-2J). bottom. 0.1 g of the obtained powder was filled in a capsule to produce an inhalation powder.
- Test Example 1 For the inhalation powders obtained in Example 1 and Comparative Example 1, the Stage 2 display rate (%) and the amount of fine particles (FPD) (%) were measured using a monoherer as a device. The results are shown in Table 1.
- Amount of fine particles (FPD) (%) was made using the multi-stage liquid impinger of the device 1 in accordance with the aerodynamic particle size measurement method of the inhalant of the 17th revision of the Japanese Pharmacopoeia.
- the inhaled powder of Example 1 has a high Stage 2 display rate (%) and fine particle amount (FPD) (%) of about 30%, and can reach deep lungs with cepharanthin. It was considered possible.
- the Stage 2 display rate (%) and the amount of fine particles (FPD) (%) were as low as about 3%, and it was considered difficult to reach the deep lung.
- Example 2 1.5 g of cepharanthin was suspended in 100 g of sterile purified water with a stirrer, 0.1 g of trometamol and 0.1 g of ethanol were added and dissolved, and 0.7 g of sodium chloride was added and dissolved to produce an inhalant.
- Cepharanthine (registered trademark) was injected to make an inhalation solution.
- Cepharanthine® Note 10 mg contains an appropriate amount of cepharanthin 10 mg as an active ingredient, benzyl alcohol 40 mg, sodium chloride 20 mg, and hydrochloric acid as additives in 2 mL (see the package insert of Cepharanthine® Note 10 mg). ).
- Test Example 2 With respect to the inhalation liquids obtained in Examples 2 and 3, it was visually confirmed whether the medicine was sprayed in the form of a mist using a nebulizer as a device. Furthermore, the atomized drug was collected and the particle size was confirmed with a microscope. The results are shown in Table 2. When the liquid was sprayed in the form of mist, a circle was marked in the table.
- Example 2 the chemical solution is sprayed in the form of a mist, and the particle size thereof is about 4 ⁇ m in Example 2 and about 5 ⁇ m in Example 3, and the chemical solutions of Examples 2 and 3 are suitable as an inhalation solution. I decided that.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
その感染力、罹患した際の重症化率等未だ不明な点があることに加え、新型であることから有効な治療法も未だ模索中であり、世界中の人々を不安に陥らせている。
これまでに、多数の既存薬物のスクリーニングがなされ、最近になって、セファランチンがCOVID-19の治療薬として期待されている(非特許文献1)。
セファランチンは、放射線による白血球減少症、円形脱毛症・粃糠性脱毛症、滲出性中耳炎、マムシ咬傷の治療に用いられている。本発明のようにセファランチンを吸入剤とした場合には、これらの適応症に加えて、SARS-CoV-2の感染抑制薬、COVID-19の予防及び/又は治療薬として特に有用である。
セファランチン含有粉末には、糖や糖アルコールを添加剤として用いることもできる。ここで、糖としては、乳糖水和物、白糖、ブドウ糖等を挙げることができ、糖アルコールとしては、エリスリトール、イソマルト、ラクチトール、マルチトール、マンニトール、ソルビトール、キシリトール等を挙げることができる。
吸入粉末剤の具体例としては、ドライパウダー吸入器(Dry Powder Inhaler;以下、DPIと略する)を挙げることができる。本発明の吸入粉末剤に用いるデバイスはDPIとして通常用いられるものを使用することができる。例えばカプセルを用いるデバイスとして、モノヘラー、ハンディヘラー、ブリーズヘラー、フローキャプス等が挙げられる。またアルミニウムのブリスターを用いるディスクヘラー、ディスカス、エリプタ等が挙げられる。
粉末を容器に充填したリザーバ型のデバイスとして、タービュヘイラー、クリックヘラー、スイングヘラー、ツイストヘラーなどが挙げられる。
吸入液剤の液滴は、ネブライザの形態(ジェット式、超音波式、メッシュ式等)に応じて、好ましくは0.5~10μm、より好ましくは1~8μm、更に好ましくは2~8μmの液滴に調整すればよく、具体的には空気動力学的質量中位径を好ましくは0.5~10μm、より好ましくは1~8μm、更に好ましくは2~8μmの液滴に調整すればよい。
本発明の吸入液剤に係るセファランチンとしては、メディサ新薬株式会社が製造販売するセファランチン(登録商標)注を用いることができる。具体的にはセファランチン(登録商標)注をそのまま、または適当な溶剤を用いて希釈して、ネブライザを用いて吸入すればよい。
本発明の吸入液剤に用いるデバイスはネブライザとして通常用いられるものを使用することができる。例えば圧縮空気で薬液を霧状にするタイプ(ジェット式)、超音波振動子の振動を利用して薬液を霧状にするタイプ(ジェット式)、振動などによって薬液をメッシュの穴から押し出して霧状にするタイプ(メッシュ式)などが挙げられる。
吸入エアゾール剤により噴霧される噴霧液滴は、セファランチンの溶液又は懸濁液の組成、充填する噴射剤や容器の部材であるノズル形状等の調整によって、好ましくは0.5~10μm、より好ましくは1~8μm、更に好ましくは2~8μmの噴霧液滴に調整すればよく、具体的には空気動力学的質量中位径を好ましくは0.5~10μm、より好ましくは1~8μm、更に好ましくは2~8μmの液滴に調整すればよい。
吸入エアゾール剤は、セファランチンを適当な溶剤を用いて、溶解又は懸濁し、溶液又は懸濁液を調製し、液状の噴射剤と共に耐圧性の容器に充填し、定量バルブを装着することにより製することができる。溶液又は懸濁液を調製するに際し、分散剤や安定化剤等を添加することができる。
吸入エアゾール剤の具体例としては、加圧噴霧式定量吸入器(Metered Dose Inhaler)を挙げることができる。
ジェットミルで粉砕したセファランチン(粒子径:1.2μm:レーザー回折法により測定)1.5gに乳糖水和物98.5gを添加し、ハイフレックスグラル(深江パウテック(株)製、HF-GS-2J)で混合した。得られた粉末0.1gをカプセルに充填して、吸入粉末剤を製造した。
未粉砕のセファランチン(粒子径:50μm:レーザー回折法により測定)1.5gに乳糖水和物98.5gを添加し、ハイフレックスグラル(深江パウテック(株)製、HF-GS-2J)で混合した。得られた粉末0.1gをカプセルに充填して、吸入粉末剤を製造した。
実施例1及び比較例1で得た吸入粉末剤について、デバイスとしてモノヘラーを用いて、Stage2表示率(%)及び微粒子量(FPD)(%)を測定した。結果を表1に示す。
(1)Stage2表示率(%)
吸入剤のIn vitro評価装置であるTwin Impingerを用いて、気道到達率であるStage2表示率を求めた。
(2)微粒子量(FPD)(%)
日本薬局方 第十七改正第二追補の吸入剤の空気力学的粒度測定法に準拠して、装置1のマルチステージリキッドインピンジャーを用いて評価した。
一方、比較例1のセファランチン未粉砕の場合は、Stage2表示率(%)及び微粒子量(FPD)(%)が3%程度と低く、肺深部までセファランチンを到達させることは困難と考えられた。
セファランチン1.5gを撹拌機にて滅菌精製水100gに懸濁し、トロメタモール0.1g、エタノール0.1gを加えて溶解し、塩化ナトリウム0.7gを加えて溶解し、吸入剤を製造した。
セファランチン(登録商標)注をして吸入液剤とした。セファランチン(登録商標)注10mgは、その組成として、2mL中に有効成分としてセファランチン10mg、添加物としてベンジルアルコール40mg、塩化ナトリウム20mg、塩酸を適量含有する(セファランチン(登録商標)注10mgの添付文書参照)。
実施例2及び3で得られた吸入液剤について、デバイスとしてネブライザを用いて、目視にて薬剤が霧状に噴霧されるかを確認した。さらに霧状とした薬剤を採取し、顕微鏡で粒子径を確認した。結果を表2に示した。液剤が霧状に噴霧された場合、表中に〇を記した。
Claims (7)
- セファランチンを含有することを特徴とする吸入剤。
- セファランチンの粒子径が0.5~10μmである請求項1記載の吸入剤。
- セファランチンを含有することを特徴とする吸入粉末剤。
- セファランチンの粒子径が0.5~10μmである請求項3記載の吸入粉末剤。
- セファランチンを含有することを特徴とする吸入液剤。
- 空気動力学的質量中位径が0.5~10μmであるセファランチンを含有する吸入剤。
- 空気動力学的質量中位径が0.5~10μmであるセファランチンを含有する吸入粉末剤。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21804702.5A EP4151211A1 (en) | 2020-05-14 | 2021-05-14 | Novel inhalant |
AU2021270426A AU2021270426A1 (en) | 2020-05-14 | 2021-05-14 | Novel inhalant |
JP2022522211A JPWO2021230340A1 (ja) | 2020-05-14 | 2021-05-14 | |
KR1020227038651A KR20230011282A (ko) | 2020-05-14 | 2021-05-14 | 신규 흡입제 |
US17/998,308 US20230338365A1 (en) | 2020-05-14 | 2021-05-14 | Novel inhalant |
CN202180035149.1A CN117083063A (zh) | 2020-05-14 | 2021-05-14 | 新型吸入剂 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020085471 | 2020-05-14 | ||
JP2020-085471 | 2020-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021230340A1 true WO2021230340A1 (ja) | 2021-11-18 |
Family
ID=78524492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/018328 WO2021230340A1 (ja) | 2020-05-14 | 2021-05-14 | 新規吸入剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230338365A1 (ja) |
EP (1) | EP4151211A1 (ja) |
JP (1) | JPWO2021230340A1 (ja) |
KR (1) | KR20230011282A (ja) |
CN (1) | CN117083063A (ja) |
AU (1) | AU2021270426A1 (ja) |
WO (1) | WO2021230340A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022177019A1 (ja) * | 2021-02-22 | 2022-08-25 | 興和株式会社 | 新規吸入剤 |
WO2023080188A1 (ja) * | 2021-11-04 | 2023-05-11 | 興和株式会社 | カプセル剤 |
WO2023080189A1 (ja) * | 2021-11-04 | 2023-05-11 | 興和株式会社 | 医薬品 |
WO2023089862A1 (ja) * | 2021-11-17 | 2023-05-25 | 国立感染症研究所長が代表する日本国 | タマサキツヅラフジ由来アルカロイド含有製剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008518007A (ja) * | 2004-10-29 | 2008-05-29 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 肺感染症の処置のための粒子 |
CN110151691A (zh) * | 2019-06-19 | 2019-08-23 | 宁夏医科大学 | 一种千金藤素纳米混悬液及其制备方法 |
-
2021
- 2021-05-14 WO PCT/JP2021/018328 patent/WO2021230340A1/ja active Application Filing
- 2021-05-14 EP EP21804702.5A patent/EP4151211A1/en not_active Withdrawn
- 2021-05-14 AU AU2021270426A patent/AU2021270426A1/en active Pending
- 2021-05-14 KR KR1020227038651A patent/KR20230011282A/ko unknown
- 2021-05-14 CN CN202180035149.1A patent/CN117083063A/zh active Pending
- 2021-05-14 JP JP2022522211A patent/JPWO2021230340A1/ja active Pending
- 2021-05-14 US US17/998,308 patent/US20230338365A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008518007A (ja) * | 2004-10-29 | 2008-05-29 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 肺感染症の処置のための粒子 |
CN110151691A (zh) * | 2019-06-19 | 2019-08-23 | 宁夏医科大学 | 一种千金藤素纳米混悬液及其制备方法 |
Non-Patent Citations (9)
Title |
---|
"The Japanese Pharmacopoeia" |
BORIS Y. SHEKUNOV, PRATIBHASH CHATTOPADHYAY, HENRY H. Y. TONG, ALBERT H. L. CHOW: "Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications", PHARMACEUTICAL RESEARCH, SPRINGER US, NEW YORK, vol. 24, no. 2, 1 February 2007 (2007-02-01), New York, pages 203 - 227, XP055572217, ISSN: 0724-8741, DOI: 10.1007/s11095-006-9146-7 * |
CIPOLLA DAVID C., IGOR GONDA: " Formulation technology to repurpose drugs for inhalation delivery", DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, ELSEVIER, AMSTERDAM, NL, vol. 8, no. 3-4, 31 December 2011 (2011-12-31), AMSTERDAM, NL , pages 123 - 130, XP055867405, ISSN: 1740-6773, DOI: 10.1016/j.ddstr.2011.07.001 * |
DONG KIM, JUNG MIN, MIN JANG, JUN LEE, YOUNG SHIN, CHUL PARK, JONG SONG, HYOUNG KIM, SEUNGTAEK KIM, YOUNG-HEE JIN, SUNOH KWON: "Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells", BIOMOLECULES, vol. 9, no. 11, pages 696, XP055737811, DOI: 10.3390/biom9110696 * |
FURUTA, SHIGERU ET AL.: "NEBULIZATION TREATMENT OF CHRONIC SINUSITIS", JIBI INKOKA TEMBO, vol. 23, no. 4, 1980, pages 11, XP009531861, ISSN: 0386-9687 * |
KAO MING-CHANG, CHEN-HSIEN YANG, JOEN-RONG SHEU, CHUN-JEN HUANG: "Cepharanthine mitigates pro-inflammatory cytokine response in lung injury induced by hemorrhagic shock/resuscitation in rats", CYTOKINE, vol. 76, 12 September 2015 (2015-09-12), pages 442 - 448, XP055867402, DOI: 10.1016/j.cyto.2015.09.008 * |
N R LABIRIS AND M B DOLOVICH: "Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY., BLACKWELL SCIENTIFIC PUBL., GB, vol. 56, no. 6, 1 December 2003 (2003-12-01), GB , pages 588 - 599, XP002735434, ISSN: 0306-5251, DOI: 10.1046/j.1365-2125.2003.01892.x * |
OHASHI HIROFUMI, WATASHI KOICHI, SASO WAKANA, SHIONOYA KAHO, IWANAMI SHOYA, HIROKAWA TAKATSUGU, SHIRAI TSUYOSHI, KANAYA SHIGEHIKO,: "Multidrug treatment with nelfinavir and cepharanthine against COVID-19", BIORXIV, 15 April 2020 (2020-04-15), XP055825394, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.04.14.039925v1.full> DOI: 10.1101/2020.04.14.039925 * |
ROGOSNITZKY MOSHE, DANKS RACHEL: "Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions", PHARMACOLOGICAL REPORTS, POLSKA AKADEMIA NAUK, INSTYTUT FARMAKOLOGII, KRAKOW, PL, vol. 63, no. 2, 1 March 2011 (2011-03-01), PL , pages 337 - 347, XP055867401, ISSN: 1734-1140, DOI: 10.1016/S1734-1140(11)70500-X * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022177019A1 (ja) * | 2021-02-22 | 2022-08-25 | 興和株式会社 | 新規吸入剤 |
WO2023080188A1 (ja) * | 2021-11-04 | 2023-05-11 | 興和株式会社 | カプセル剤 |
WO2023080189A1 (ja) * | 2021-11-04 | 2023-05-11 | 興和株式会社 | 医薬品 |
WO2023089862A1 (ja) * | 2021-11-17 | 2023-05-25 | 国立感染症研究所長が代表する日本国 | タマサキツヅラフジ由来アルカロイド含有製剤 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2021230340A1 (ja) | 2021-11-18 |
EP4151211A1 (en) | 2023-03-22 |
US20230338365A1 (en) | 2023-10-26 |
KR20230011282A (ko) | 2023-01-20 |
AU2021270426A1 (en) | 2022-12-08 |
CN117083063A (zh) | 2023-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021230340A1 (ja) | 新規吸入剤 | |
AU2002244211B2 (en) | Aerosol Compositions Containing Formoterol for Delivery to the Lungs via Nebulization | |
TWI758617B (zh) | 包含格隆銨鹽及茚達特羅鹽的氣霧劑藥物組合物、其製備方法與用途 | |
CN1304290A (zh) | 雷洛昔芬的肺和鼻传递给药 | |
AU2002244211A1 (en) | Aerosol Compositions Containing Formoterol for Delivery to the Lungs via Nebulization | |
KR20110120283A (ko) | 흡입용 약학적 조성물 | |
Ariyananda et al. | Aerosol delivery systems for bronchial asthma | |
US20210386697A1 (en) | Peramivir solution type inhalant and preparation method therefor | |
WO2019119720A1 (zh) | 一种福多司坦雾化吸入用溶液制剂及其制备方法 | |
US11304897B2 (en) | Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate | |
US20210386730A1 (en) | Pharmaceutical formulation containing glycopyrrolate and indacaterol maleate | |
CN111358773B (zh) | 一种帕拉米韦干粉吸入剂及其制备方法 | |
JP2002532405A (ja) | オピオイド吸入製剤 | |
EP2821061A1 (en) | Novel inhalation formulations | |
CN110179772A (zh) | 一种可供雾化吸入用的盐酸氨溴索制剂及其制备方法 | |
US20230158067A1 (en) | Silver nanoparticles for use in inhibiting and treating coronavirus infection | |
TW200922600A (en) | DHEAS inhalation compositions | |
WO2023003003A1 (ja) | 新規吸入剤 | |
WO2021262675A1 (en) | Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide | |
CN111110634A (zh) | 一种磷酸氯喹吸入气雾剂及其制备方法 | |
JP2024049405A (ja) | 新規吸入剤 | |
CN116196298A (zh) | 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用 | |
WO2023068287A1 (ja) | 新規医薬 | |
KR102250876B1 (ko) | 티오트로피움 또는 이의 약학적으로 허용가능한 염을 포함하는 흡입용 건조분말 조성물 | |
CN114432365A (zh) | 一种痰热清雾化吸入制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21804702 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022522211 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180035149.1 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2021270426 Country of ref document: AU Date of ref document: 20210514 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021804702 Country of ref document: EP Effective date: 20221214 |